利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

1664 条记录 (耗时 0.035 秒)

    Covalently fused viral coat proteins for the display of target molecules
    3.
    发明授权
    Covalently fused viral coat proteins for the display of target molecules 有权

    公开(公告)号：US11618771B2

    公开(公告)日：2023-04-04

    申请号：US17361835

    申请日：2021-06-29

    申请人： Fraunhofer USA Inc.

    发明人： Stephen Tottey ,  Konstantin Musiychuk

    IPC分类号： A61K39/12 ,  A61K39/00 ,  C07K14/005 ,  C07K14/415 ,  C12N7/01 ,  A61K39/015 ,  C12N15/11

    摘要： A fusion protein comprising a target protein, a first recombinant viral coat protein, a second recombinant viral coat protein and a first linkage peptide is provided. The target protein is at N-terminus of the first recombinant viral coat protein. The first recombinant viral coat protein is linked to N-terminus of the first linkage peptide. The second recombinant viral coat protein is linked to C-terminus of the first linkage peptide. The first and second recombinant viral coat proteins are derived from the coat protein (CP) of alfalfa mosaic virus (AIMV). The fusion protein may further comprise a second linkage peptide between the target protein and the first recombinant viral coat protein. The fusion protein may form a virus like particle (VLP). The target protein may be displayed on the surface of the VLP. Also provided are methods for producing the fusion protein and the VLP as well as the uses of the fusion protein and/or the VLP.

    Method of producing a polypeptide or virus of interest in a continuous cell culture
    8.
    发明授权
    Method of producing a polypeptide or virus of interest in a continuous cell culture 有权

    公开(公告)号：US09650612B2

    公开(公告)日：2017-05-16

    申请号：US14050710

    申请日：2013-10-10

    申请人： Baxalta GmbH ,  Baxalta Incorporated

    发明人： Leopold Grillberger ,  Manfred Reiter ,  Daniel Fleischanderl

    IPC分类号： C12N5/00 ,  C12N7/01 ,  C12N15/86 ,  C12N7/00 ,  C12N9/64 ,  C12P21/02

    CPC分类号： C12N7/00 ,  C12N9/6489 ,  C12N2710/00052 ,  C12P21/02 ,  Y02P20/52

    摘要： Described herein is a chemostat-like continuous cell culture system that combines certain advantages of perfusion open systems and chemostat open systems to improve the culturing of mammalian cells, e.g., genetically modified cells, particularly in serum-free or chemically-defined media. The continuous culture system described herein involves culturing mammalian cells in a continuous cell culture system, which comprises a cell retention device, wherein the cell culture system has a dilution rate (D) of less than about 2 d−1, and a cell density of less than about 2×107 cell/mL. Also described herein is a method for producing a polypeptide and/or virus of interest in a continuous cell culture, the method comprising culturing mammalian cells expressing the polypeptide and/or virus of interest in a continuous cell culture system, which comprises a cell retention device, wherein the cell culture system has a dilution rate (D) of less than about 2 d−1, and a cell density of less than about 2×107 cell/mL; and recovering the polypeptide and/or virus of interest from medium of the cell culture system.

    Method for cancer immunotherapy and pharmaceutical compositions based on oncolytic non-pathogenic Sendai virus
    10.
    发明授权
    Method for cancer immunotherapy and pharmaceutical compositions based on oncolytic non-pathogenic Sendai virus 有权
    基于溶瘤非致病性仙台病毒的癌症免疫治疗方法和药物组合物

    公开(公告)号：US09526779B2

    公开(公告)日：2016-12-27

    申请号：US14438545

    申请日：2013-11-21

    申请人： Anna Senina

    发明人： Olga Matveeva ,  Anna Senina ,  Vyacheslav Slav Mikhailovich Senin

    IPC分类号： A61K39/155 ,  A61K39/00 ,  A61K39/12 ,  A61K9/00 ,  C12N7/00 ,  C12N7/01

    CPC分类号： A61K39/155 ,  A61K9/0019 ,  A61K39/0011 ,  A61K39/12 ,  A61K2039/515 ,  A61K2039/5152 ,  A61K2039/525 ,  A61K2039/54 ,  A61K2039/552 ,  A61K2039/585 ,  C12N7/00 ,  C12N2760/18834 ,  C12N2760/18871 ,  A61K2300/00

    摘要： The invention relates to the field of immunology and medicine, more specifically, oncology, and can be useful for the treatment of patients with carcinomas and sarcomas. A pharmaceutical composition is provided which contains biologically active oncolytic Sendai virus strain Moscow PTA-13024, and a method of treating patients with said malignancies is developed including administration of the said composition to a patient's body. The strain Sendai-Moscow deposited into ATCC as frozen allantoic fluid (deposit PTA-13024) and as lyophilized form (deposit PTA-121432) is characterized by high oncolytic activity and safety for humans. The exploitation of the invention allows an increase in efficacy of treatment due to direct elimination of malignant cells via virus action and induction of anti-tumor immunity by viruses.

    摘要翻译： 本发明涉及免疫学和医学领域，更具体地涉及肿瘤学，并且可用于治疗患有癌和肉瘤的患者。 提供含有生物活性溶瘤仙台病毒株莫斯科PTA-13024的药物组合物，并且开发了治疗患有所述恶性肿瘤的患者的方法，包括将所述组合物施用于患者的身体。 仙台莫斯科菌株作为冷冻尿囊液（沉淀物PTA-13024）和冻干形式（沉积物PTA-121432）保藏在ATCC中，其特征在于高的溶瘤活性和人的安全性。 本发明的开发允许通过病毒作用直接消除恶性细胞并通过病毒诱导抗肿瘤免疫来提高治疗效果。